| Ticker Details |
Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company. Its business model is based upon the concept of acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure.
|
| IPO Date: |
September 7, 2005 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$4.1B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.42 | 2.11%
|
| Avg Daily Range (30 D): |
$3.71 | 1.81%
|
| Avg Daily Range (90 D): |
$3.20 | 1.62%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.27M |
| Avg Daily Volume (30 D): |
.17M |
| Avg Daily Volume (90 D): |
.16M |
| Trade Size |
| Avg Trade Size (Sh.): |
88 |
| Avg Trade Size (Sh.) (30 D): |
30 |
| Avg Trade Size (Sh.) (90 D): |
30 |
| Institutional Trades |
| Total Institutional Trades: |
5,575 |
| Avg Institutional Trade: |
$3.18M |
| Avg Institutional Trade (30 D): |
$5.95M |
| Avg Institutional Trade (90 D): |
$5.19M |
| Avg Institutional Trade Volume: |
.03M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.31M |
| Avg Closing Trade (30 D): |
$6.19M |
| Avg Closing Trade (90 D): |
$5.57M |
| Avg Closing Volume: |
29.81K |
|
|
| Financials |
| |
TTM |
Q4 2025 |
FY 2025 |
|
Basic EPS
|
$6.44
|
$2.33
|
$6.44
|
|
Diluted EPS
|
$6.13
|
$2.18
|
$6.13
|
|
Revenue
|
$268.09M
|
$59.67M
|
$268.09M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
$124.45M
|
$44.78M
|
$124.45M
|
|
Operating Income / Loss
|
$41M
|
$13.84M
|
$41M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
$102.62M
|
$35.55M
|
$102.62M
|
|
PE Ratio
|
33.43
|
|
|
|
|
|
